Abstract
<i>Background: </i>Metastatic breast cancer is a common and devastating diagnosis. New strategies for treatment are needed to help improve outcomes. Eribulin is an anti-microtubule agent approved in 2010 for advanced breast cancer. Combination with other chemotherapeutic agents provides an alternative treatment option for these patients. <i>Purpose:</i> This study evaluates the safety, tolerability and activity of eribulin and weekly carboplatin in a dose-escalation schema in patients with metastatic breast cancer. <i>Methods:</i> Patients were treated with eribulin and carboplatin AUC 2 administered on the first and eighth days of a 21-day cycle. Three doses of eribulin (0.9, 1.1 and 1.4 mg/m<sup>2</sup>) were examined. An additional 10 patients were enrolled into an expansion cohort at the recommended Phase 2 dose. <i>Results:</i> A total of 19 patients were treated, including 10 patients in the dose expansion cohort. There was no dose limiting toxicity related to the study therapy in the dose escalation cohorts. Grade 3 toxicities included neutropenia (21%), anemia (10%), fatigue (10%), peripheral sensory neuropathy (10%), infusion related reactions (5%), pericardial effusion (5%), diarrhea (5%) and pleural effusion (5%). Twenty-six percent of patients had grade 4 neutropenia, but there were no events of sepsis or febrile neutropenia. The maximum tolerated dose (MTD) of eribulin in combination with carboplatin AUC 2 was determined to be 1.4 mg/m<sup>2</sup>. Four patients experienced clinical benefit, 2 patients with stable disease greater than 6 months and 2 patients with partial response, demonstrating a clinical benefit rate of 21%. <i>Conclusion: </i>Eribulin and weekly carboplatin appeared to be safe and well tolerated with demonstrated clinical benefit. The recommended Phase 2 dose level was 1.4 mg/m<sup>2</sup> of eribulin. Further studies can be pursued for this combination regimen to establish its efficacy.
Highlights
Breast cancer is the most commonly diagnosed malignancy after skin cancers
Carboplatin for the Treatment of Metastatic Breast Cancer agents are typically administered in the adjuvant setting
[7] It is an analogue of halichondrin B, a naturally occurring substance found in marine sponges. [6, 8] It acts on microtubules with a mechanism of action that is distinct from the taxanes. [9,10,11,12] In the pivotal Phase III trial which led to this approval, the patient population received both anthracycline and taxane prior to eribulin
Summary
Breast cancer is the most commonly diagnosed malignancy after skin cancers. Metastatic breast cancer has a median overall survival approaching two years, an improvement over the last 25 years likely related to improved hormonal, targeted and chemotherapeutic agents.[3] Anthracyclines and taxanes, have been associated with improved overall survival, and these. Aixa Elena Soyano et al.: A Phase 1 Dose Escalation Study of Eribulin in Combination with. Carboplatin for the Treatment of Metastatic Breast Cancer agents are typically administered in the adjuvant setting. In 2010, eribulin was approved to treat metastatic breast cancer in patients who received at least two prior chemotherapy regimens. Eribulin is an anti-microtubule agent approved in 2010 for advanced breast cancer. Purpose: This study evaluates the safety, tolerability and activity of eribulin and weekly carboplatin in a dose-escalation schema in patients with metastatic breast cancer. Further studies can be pursued for this combination regimen to establish its efficacy
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
